The immunity of another anti-CTLA-4 mAb, tremelimumab, was evaluated as a single treatment or with anti-PD-L1 (durvalumab) in advanced breast cancer treatment (NCT02527434 and NCT01975831). This evidence concerns the gene CD274 and breast carcinoma.